As the FDA halts the use of Regeneron and Eli Lilly treatments for COVID-19, the supply remains scarce of a newer drug from GlaxoSmithKline and Vir Biotechnology.
As the FDA halts the use of Regeneron and Eli Lilly treatments for COVID-19, the supply remains scarce of a newer drug from GlaxoSmithKline and Vir Biotechnology.